Rahul Banerjee, MD
In this video playlist, Rahul Banerjee, MD, assistant professor in the clinical research division at Fred Hutchinson Cancer Center, discussed:
- the latest developments in the treatment and study of relapsed/refractory multiple myeloma, including insight into the study of measurable residual disease;
- the impact that chimeric antigen receptor T-cell therapy has made on multiple myeloma, which he said has allowed doctors to “change their paradigm”;
- how CAR-T has helped change outcomes in multiple myeloma, and relevant data from the KarMMa-3 trial;
- insight into specific indicators of relapse in multiple myeloma, a major subject of debate over the last 20 years;
- how he approaches predicting and treating multiple myeloma relapse in his own practice; and
- the biggest unmet needs in the treatment of relapsed/refractory multiple myeloma, and obstacles towards curing the disease.